QTORIN rapamycin 3.9 percent gel

Name: QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Clinical presentation - signs and symptoms
Published: 2026-09-14T15:39:06-04:00

Microcystic lymphatic malformations

Manufacturer: Palvella Therapeutics
Regulatory submission: NDA submitted August 2026
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Clinical presentation - signs and symptoms

3 evidence topics · 3 sources

Cutaneous symptoms: lymphorrhea, bleeding, pain, itching, and malodor

“lymphorrhea, bleeding, pain, itching, malodor, and functional deficits.” (opens the source at this quote in a new tab)

Infectious and inflammatory symptoms: pain and chronic oozing wounds

“LMs are also highly immunologically reactive, and are prone to recurrent infections and inflammation causing pain as well as chronic oozing wounds.” (opens the source at this quote in a new tab)

Oral and airway symptoms: tongue involvement

“hemorrhage, excessive salivation, speech disturbances, difficulties chewing and swallowing, airway obstruction, and orthodontic abnormalities” (opens the source at this quote in a new tab)